Cost-of-illness studies in systemic lupus erythematosus: A systematic review

Arthritis Care and Research

Volumn 63, Issue 5, 2011, Pages 751-760

  Zhu, Tracy Y ^a,b   Tam, Lai Shan ^a   Li, Edmund K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST OF ILLNESS; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; MEDICAL LEAVE; MEDLINE; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; WORK CAPACITY;

ADULT; COST OF ILLNESS; EMPLOYMENT; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INPATIENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MODELS, ECONOMIC; RESEARCH DESIGN; SICK LEAVE; TREATMENT OUTCOME;

EID: 79958818391     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20410     Document Type: Article

References (33)

1. Rice DP. Estimating the cost of illness. Am J Public Health Nations Health 1967;57:424-40.
2. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982;60:429-62.
3. Rascati KL. Measuring and estimating costs. In: Essentials of pharmacoeconomics. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009. p. 9-23.
4. Fautrel B, Guillemin F. Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol 2002;14:121-6. (Pubitemid 34185293)
5. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:28-33. (Pubitemid 30095403)
6. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20. (Pubitemid 30235982)
7. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006;15:308-18. (Pubitemid 43828810)
8. Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy 2006;77:51-63.
9. Rothfuss J, Mau W, Zeidler H, Brenner MH. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review. Semin Arthritis Rheum 1997;26:771-9. (Pubitemid 27190964)
10. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992;2:1-4.
11. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:1-7.
12. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.
13. Clarke AE, Esdaile JM, Bloch DA, Lacaille D, Danoff DS, Fries JF. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993;36:1548-59. (Pubitemid 23327753)
14. Clarke AE, Bloch DA, Danoff DS, Esdaile JM. Decreasing costs and improving outcomes in systemic lupus erythematosus: using regression trees to develop health policy. J Rheumatol 1994;21:2246-53.
15. Lacaille D, Clarke AE, Bloch DA, Danoff D, Esdaile JM. The impact of disease activity, treatment and disease severity on short-term costs of systemic lupus erythematosus. J Rheumatol 1994;21:448-53. (Pubitemid 24102828)
16. Clarke AE, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. The systemic lupus erythematosus Tri-Nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) 2004;43:1016-24. (Pubitemid 39144449)
17. Clarke AE, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus: Tri-Nation Study Group. J Rheumatol 1999; 26:1500-11. (Pubitemid 29317872)
18. Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. The systemic lupus erythematosus Tri-Nation Study: cumulative indirect costs. Arthritis Rheum 2007;57: 64-70.
19. Clarke AE, Penrod J, St Pierre Y, Petri MA, Manzi S, Isenberg DA, et al. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus: Tri-Nation Study Group. J Rheumatol 2000;27:2597-604.
20. Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001;40:37-47.
21. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83. (Pubitemid 44277392)
22. Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008;59:1788-95.
23. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009;61:1159-67.
24. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. Rheumatology (Oxford) 2009;48:564-8.
25. Carls G, Li T, Panopalis P, Wang S, Mell AG, Gibson TB, et al. Direct and indirect costs to employers of patients with sys-temic lupus erythematosus with and without nephritis. J Occup Environ Med 2009;51:66-79.
26. Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis Rheum 2009;61: 755-63.
27. Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin Ther 2009;31:2653-64.
28. Clarke AE, Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 2008;47:329-33. (Pubitemid 351267201)
29. Gordon C, Clarke AE. Quality of life and economic evaluation in SLE clinical trials. Lupus 1999;8:645-54. (Pubitemid 29520531)
30. Mooney G, Wiseman V. Burden of disease and priority setting. Health Econ 2000;9:369-72. (Pubitemid 30612140)
31. Koopmanschap MA. Cost-of-illness studies: useful for health policy? Pharmacoeconomics 1998;14:143-8. (Pubitemid 28370825)
32. Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision making? Health Policy 1987;8:317-23.
33. Dall'Era M, Wofsy D. Connective tissue diseases. Belimumab for systemic lupus erythematosus: breaking through? Nat Rev Rheumatol 2010;6:124-5.